Given the important role of IFNγ/STAT1/PD-L1 axis in innate and adaptive immune responses, targeting the IFNγ signaling pathway could improve treatment efficacy for UC or CRC treatment. The gene discussed is STAT1; the disease is colorectal carcinoma.